GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.94% | -91.26% | -76.10% | -18.66% | 18.54% |
| Total Other Revenue | -39.19% | -37.78% | -35.63% | -35.18% | -33.67% |
| Total Revenue | -73.33% | -64.57% | -52.08% | -28.24% | -11.36% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -73.33% | -64.57% | -52.08% | -28.24% | -11.36% |
| SG&A Expenses | -9.30% | -21.79% | -30.19% | -45.71% | -54.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.04% | -30.22% | -26.18% | -37.30% | -43.51% |
| Operating Income | 27.52% | 25.80% | 23.62% | 38.20% | 46.72% |
| Income Before Tax | 10.50% | 19.16% | 24.43% | 37.79% | 46.66% |
| Income Tax Expenses | -122.91% | -92.37% | 134.38% | 856.25% | -- |
| Earnings from Continuing Operations | 10.67% | 19.21% | 24.40% | 37.74% | 46.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.67% | 19.21% | 24.40% | 37.74% | 46.58% |
| EBIT | 27.52% | 25.80% | 23.62% | 38.20% | 46.72% |
| EBITDA | 23.44% | 20.87% | 17.85% | 35.95% | 46.35% |
| EPS Basic | 40.04% | 56.57% | 63.16% | 69.51% | 73.09% |
| Normalized Basic EPS | 39.88% | 56.57% | 63.19% | 69.56% | 73.13% |
| EPS Diluted | 40.04% | 56.57% | 63.16% | 69.51% | 73.09% |
| Normalized Diluted EPS | 39.88% | 56.57% | 63.19% | 69.56% | 73.13% |
| Average Basic Shares Outstanding | 54.91% | 64.31% | 77.81% | 86.31% | 98.10% |
| Average Diluted Shares Outstanding | 54.91% | 64.31% | 77.81% | 86.31% | 98.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |